{"classes":[{"categories":[{"measurements":[{"comment":"The median, lower limit and upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"7.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"DOR was defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented PD per RECIST v1.1 as assessed by BICR, or death due to any cause. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: \\>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm for target disease or unequivocal progression of pre-existing lesions for non-target disease or any new lesion. Analysis was performed using Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Cohort 3: Arm D [EC + FOLFIRI]"},{"description":"Participants received fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W with or without bevacizumab. Bevacizumab was optional and it was given per prescribing instructions of treating physician. Participants received treatment in 28-day cycles.","id":"OG001","title":"Cohort 3: Arm E [FOLFIRI With or Without Bevacizumab]"}],"paramType":"MEDIAN","populationDescription":"The FAS for Cohort 3 included all participants who were randomized in the Cohort 3 portion of the study, respectively. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure with a confirmed objective response as assessed by BICR.","reportingStatus":"POSTED","timeFrame":"From date of first radiographic evidence of response (CR or PR) to earliest documented PD or death due to any cause, whichever occurred first (maximum up to 14.1 months)","title":"Cohort 3: DOR as Assessed by BICR - FAS","type":"SECONDARY","unitOfMeasure":"Months"}